FGL (FGLL): Evidence, Mechanism, Dosing & Legal Status

FGL (also written FGLL, the "FG loop peptide") is a 15-amino-acid synthetic peptide — sequence EVYVVAENQQGKSKA — derived from the second fibronectin type III module of the neural cell adhesion molecule (NCAM), and marketed in research-chemical and biohacking circles as a memory and brain-protection peptide.3 Its popularity online outruns its proof in people. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. FGL is an investigational, non-approved peptide with no efficacy proven in humans; it is sold as a "research chemical not for human use." Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is FGL and how does it work?

FGL is a 15-residue synthetic peptide corresponding to the FG loop region of the second F3 module of NCAM; the FG loop was identified by NMR titration as NCAM's binding site for fibroblast growth factor receptor 1 (FGFR1).3 Because monomeric peptides activate receptors weakly, FGL is typically synthesized and dosed as a dendrimeric dimer or tetramer — for example a four-monomer dendrimer on a lysine core — to promote FGFR dimerization and downstream signaling.39 The "FGLL" form refers to the low-molecular-weight variant suitable for parenteral and intranasal delivery.1

The core mechanism — all of it preclinical — centers on FGFR1 activation. FGL binds the Ig3 module of FGFR1 and induces receptor phosphorylation, mimicking the physiological NCAM-FGFR interaction at the cell surface.3 Activated FGFR1 triggers the canonical neurotrophic cascades — FRS2-alpha, ShcA, PLC-gamma, the Ras-MAPK (Erk1/2) arm and the PI3K-Akt arm — which together drive neurite outgrowth, neuronal survival and synaptic remodeling.3 In primary hippocampal neurons FGL enhances presynaptic function and promotes synapse formation in an FGFR1-dependent manner, and it drives activity-dependent delivery of glutamate receptors to synapses.2 It also exerts anti-inflammatory effects by modulating microglial activation and IGF-1 / interferon-gamma signaling.13 Preclinical pharmacokinetics in rats, dogs and monkeys showed measurable exposure in plasma and cerebrospinal fluid after both parenteral and intranasal dosing, the basis for the "nose-to-brain" delivery strategy; a precise human elimination half-life is not robustly characterized.1

What is the evidence by indication?

Every efficacy claim for FGL is preclinical and graded C. The single human study measured safety and pharmacokinetics, not efficacy, and no randomized controlled trial exists for any indication.1

The memory data are the most cited. Intracerebroventricular FGL given immediately after fear conditioning or water-maze training produced a long-lasting improvement in memory in rats, and in vitro FGL enhanced presynaptic function and synapse formation — the first evidence that mimicking NCAM facilitates memory.2 Intranasal FGL accelerated early postnatal sensorimotor development and subcutaneous FGL prolonged social memory in adult rats, and FGL reversed cognitive deficits in a neonatal PCP model.45 For neuroprotection, a single suboccipital pretreatment 24 hours before insult protected hippocampal CA1 neurons in a gerbil global-ischemia model, and after middle cerebral artery occlusion subcutaneous FGL mobilized endogenous neural stem cells (confirmed by PET and histology) — though that study reported no infarct-volume or functional-outcome data.67 In Alzheimer's models, systemic FGL alleviated amyloid-beta-induced CA1 cell loss and prevented expected memory deficits in rats.8 In aged 22-month rats it attenuated glial activation and remodeled dentate-gyrus synapses.1011

The one important counter-signal is in epilepsy. In a mouse amygdala-kindling model, subcutaneous FGL at 2 and 10 mg/kg reduced the number of stimulations needed to reach generalized seizure, and the authors concluded FGL showed no disease-modifying benefit and raised concern about possible pro-epileptogenic network promotion — a negative, safety-relevant finding rather than a therapeutic one.9

The only human data are a single Phase 1 study. A 2007 open-label, 8-day trial gave single ascending intranasal doses (25, 100, 200 mg) to 24 healthy male volunteers in a sequential-cohort design; all doses were well tolerated with no clinically notable abnormalities and a generally dose-related pharmacokinetic profile. Critically, it assessed tolerability, safety and pharmacokinetics only — there was no cognitive or clinical efficacy endpoint. The full record is on PubMed (PMID 17375985), and this human data does not lift any efficacy claim above Grade C.1

What doses appear in the literature?

Reported strictly as information, not a protocol — no validated human therapeutic dose exists.1 In rodent work the subcutaneous minimum effective dose was about 0.2 mg/kg for neuroprotection and roughly 0.8 mg/kg for amyloid-beta-related memory rescue, while the kindling study used 2 and 10 mg/kg; subcutaneous, intracerebroventricular and intranasal routes were all employed.92 The only human exposure was the 2007 Phase 1 study, which used single intranasal doses of 25, 100 and 200 mg framed as ranging from expected minimum-effective to highest well-tolerated — a single-dose safety study, not a repeat-dosing therapeutic regimen.1 Anecdotal research-chemical write-ups cite roughly 1 to 2 mg subcutaneously per day or intranasal microgram doses on cycling schedules, but these are unvalidated, are not from controlled human trials, and carry unknown risk; community reports are mixed, with some users reporting subjective effects and others reporting nothing even at high doses.1718

How safe is FGL?

Human safety data are extremely limited: the single-dose Phase 1 study found intranasal doses up to 200 mg well tolerated in 24 healthy men, with no clinically notable ECG, vital-sign or laboratory abnormalities — but that covers single-dose, short-term exposure only.1 Preclinically, no systemic toxicity was reported in rats, dogs or monkeys at the doses studied.3 Two cautions dominate. First, the mouse kindling study's pro-epileptogenic signal argues against assuming benign neuro-stimulation, particularly for anyone with a seizure history.9 Second, as an FGFR1 agonist, chronic FGL activates a receptor axis implicated in cell proliferation and angiogenesis, making sustained systemic activation a plausible theoretical concern for tumor promotion — though no FGL study has demonstrated this; it is a mechanistic caution, not an observed harm. Long-term and repeat-dose human safety is unknown, no drug interactions are characterized in humans, and pregnancy, lactation, active or prior malignancy, and seizure disorders are precautionary contraindications given the absence of data. Anecdotal reports for an experimental HA-FGL variant mention anxiety and sleep disturbance.17

What is the FDA and WADA status in 2026?

FGL/FGLL is not FDA-approved for any indication and has no labeled use. It is not an established 503A or 503B compounding bulk substance — it does not appear on FDA's approved compounding bulk-drug lists — so no FDA-regulated pharmacy may legally compound it, and vendors sell it explicitly as a "research chemical, not for human use," which confers no legality for human administration.15 On development: the originator, Enkam Pharmaceuticals of Copenhagen, advanced FGL through Phase 1 and announced intent to start Alzheimer's trials of a modified form around 2012, but no Phase 2/3 efficacy program is publicly documented, the asset is listed only as "Pending," and FGL is absent from the 2024 Alzheimer's pipeline review — consistent with stalled or discontinued development as of 2026.14

For athletes the picture requires care. FGL/FGLL is not specifically named on the WADA Prohibited List, but as a non-approved investigational substance with cognitive and neuro-active intent it could plausibly be captured by the list's catch-all for substances not approved for human therapeutic use; athletes should verify against the current WADA Prohibited List rather than rely on absence of a named entry.16 FGL is not a DEA-controlled substance.

Bottom line. FGL (FGLL) pairs a genuinely substantial, internally consistent rodent evidence base with a near-total absence of human proof: across multiple independent models it enhances synaptogenesis and memory, protects neurons against ischemic and amyloid-beta insults, and mobilizes neural stem cells — all Grade C. What it lacks is the thing that matters most for human use: any controlled human efficacy evidence. The sole clinical study established short-term intranasal tolerability and basic pharmacokinetics — safety, not efficacy — and development has since stalled. Add a preclinical pro-epileptogenic signal and a theoretical FGFR-axis proliferation liability, and the honest verdict is that the marketed cognition claims are hype that outruns the evidence. Regulatory facts here are current as of June 2026 and should be re-verified, as the status of an investigational asset can change.